Emily Smith, MD
Dermatopathology · Saint Louis, MONPI 1528324670
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,248 of the $2,506 with a category attached, or 89.7%. Sanofi accounts for 89.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $2,248 and has fallen 94.6% since, to $121 in 2025.
Across 4 payments — averaging $626.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- E.r. Squibb & Sons, L.L.C.$121
- Novo Nordisk$117
- Abbott$20
Across 14 payments — averaging $4161.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$58K
What the payments were for
- Consulting fees$2,24890%
- Food & beverage$25810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 1 | $2,248 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Novo Nordisk | 1 | $117 |
| Abbott | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few dermatopathology providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 26 | $119,223 |
| Dupixent PenDupilumab | 24 | $96,329 |
| Clobetasol Propionate | 55 | $7,863 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 31 | $2,685 |
| Tacrolimus | 15 | $2,329 |
| Clindamycin Phosphate | 50 | $2,077 |
| Metronidazole | 24 | $1,625 |
| Ketoconazole | 84 | $1,199 |
| Triamcinolone Acetonide | 66 | $835 |
| Fluocinonide | 14 | $601 |
| Doxycycline Hyclate | 13 | $520 |
| Doxycycline Monohydrate | 21 | $432 |
| Hydroxyzine Hcl | 13 | $218 |
| Mupirocin | 16 | $132 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Saint Louis
- M Yadira HurleySaint Louis$12K
- Georgeanne CornellSaint Louis$3K
- Kristine SmithSaint Louis$133
- Mark HurtMaryland Heights$2K
- Sarah WalshMaryland Heights$1K
- Kara LefevreColumbia$193
- William BlankChaffee$28
- Cecilia RosalesKansas City$18
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.